PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28385543-0 2017 Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 89-93 28385543-6 2017 Our study suggests that both SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. Rosuvastatin Calcium 86-98 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 41-46 28385543-6 2017 Our study suggests that both SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. Rosuvastatin Calcium 185-197 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 41-46 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 275-307 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 309-313 27737931-3 2017 Although each of these transporters is believed to play a role in rosuvastatin disposition, multiple pharmacogenetic studies confirm that OATP1B1 and BCRP play an important role in vivo. Rosuvastatin Calcium 66-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 150-154 27557342-0 2016 Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. Rosuvastatin Calcium 88-100 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 55-60 27651239-0 2016 Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. Rosuvastatin Calcium 164-176 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 136-141 27651239-1 2016 PURPOSE: The ATP-binding cassette transporter G2 (ABCG2) plays an important role in the disposition of rosuvastatin. Rosuvastatin Calcium 103-115 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 13-48 27651239-1 2016 PURPOSE: The ATP-binding cassette transporter G2 (ABCG2) plays an important role in the disposition of rosuvastatin. Rosuvastatin Calcium 103-115 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-55 27651239-11 2016 The in vitro experiment demonstrated that telmisartan inhibited ABCG2-mediated efflux of rosuvastatin. Rosuvastatin Calcium 89-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 64-69 27557342-2 2016 This study was designed to investigate whether the genetic variants in drug disposition genes (SLCO1B1 and ABCG2) combined with their upstream regulators (NR1H4 and NR1I2) would affect the PKs of rosuvastatin in a Chinese population. Rosuvastatin Calcium 196-208 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 107-112 27557342-5 2016 The exposure of rosuvastatin was higher in subjects carrying the SLCO1B1 521C or ABCG2 421A allele compared with noncarriers. Rosuvastatin Calcium 16-28 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 81-86 26700956-9 2016 In conclusion, solitary inhibition of the intestinal BCRP transporter can result in clinically significant DDIs with rosuvastatin, causing up to a maximum 2-fold increase in exposure, which may warrant statin dose adjustment in clinical practice. Rosuvastatin Calcium 117-129 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 53-57 27146814-1 2016 PURPOSE: Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). Rosuvastatin Calcium 9-21 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 121-125 27146814-1 2016 PURPOSE: Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). Rosuvastatin Calcium 9-21 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 127-132 27146814-2 2016 The objective of our study was to investigate the effects of pantoprazole, a previously proposed BCRP inhibitor, on the disposition of rosuvastatin. Rosuvastatin Calcium 135-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 97-101 26700956-0 2016 Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Rosuvastatin Calcium 142-154 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-59 26700956-1 2016 The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the absorption of rosuvastatin. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-66 26700956-1 2016 The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the absorption of rosuvastatin. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-72 26700956-2 2016 Of the transporters important to rosuvastatin disposition, fostamatinib inhibited BCRP (IC50 = 50 nM) and organic anion-transporting polypeptide 1B1 (OATP1B1; IC50 > 10 muM), but not organic anion transporter 3, in vitro, predicting a drug-drug interaction (DDI) in vivo through inhibition of BCRP only. Rosuvastatin Calcium 33-45 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 82-86 26700956-4 2016 This confirmed the critical role BCRP plays in statin absorption, as inhibition by fostamatinib resulted in a significant 1.96-fold and 1.88-fold increase in rosuvastatin area under the plasma concentration-time curve (AUC) and Cmax, respectively. Rosuvastatin Calcium 158-170 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 33-37 25673568-5 2015 Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Rosuvastatin Calcium 101-113 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-73 25630984-12 2015 This study suggests that polymorphisms in the SLCO1B1 and ABCG2 genes contribute to the variability in rosuvastatin exposure. Rosuvastatin Calcium 103-115 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 58-63 26081159-0 2015 Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote. Rosuvastatin Calcium 21-33 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 75-80 26081159-1 2015 Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor used to lower blood low-density lipoprotein cholesterol, is a substrate of the membrane ABCG2 exporter. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 162-167 26081159-2 2015 ABCG2 variants have been shown to alter rosuvastatin disposition. Rosuvastatin Calcium 40-52 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 26081159-3 2015 The objective of this study is to determine the impact of ABCG2 34/421 compound haplotypes on rosuvastatin pharmacokinetics in healthy Chinese volunteer subjects. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 58-63 26081159-11 2015 A high frequency of ABCG2 c.34G>A and c.421C>A variants was present in Chinese males, and the disposition of rosuvastatin was significantly affected by both variants. Rosuvastatin Calcium 115-127 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 20-25 25740267-2 2015 To understand the relevance of these in vitro findings, a clinical pharmacokinetic DDI study using rosuvastatin as a BCRP, OATP, and OAT3 probe substrate was conducted. Rosuvastatin Calcium 99-111 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 117-121 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-43 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 198-203 25673568-9 2015 In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-68 23930675-0 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 28-33 24440960-0 2014 Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. Rosuvastatin Calcium 64-76 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 81-113 24440960-10 2014 These results suggest that BCRP in small intestine may be the major target for interaction between ELT and rosuvastatin in humans. Rosuvastatin Calcium 107-119 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-31 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 237-269 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 271-275 23881596-10 2014 Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers. Rosuvastatin Calcium 177-189 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 143-147 23930675-4 2013 RESULTS: In subjects with the ABCG2 421AA genotype (n = 39), the mean plasma concentrations of rosuvastatin and its metabolite were 63 and 41% greater than the values in those with the 421CA genotype (n = 108) and 120 and 99% greater than in those with the 421CC genotype (n = 129). Rosuvastatin Calcium 95-107 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 30-35 23930675-5 2013 The plasma concentrations of rosuvastatin were associated (r = -0.194; p = 0.001) with the percentage reduction in low-density lipoprotein cholesterol with rosuvastatin, but the association was not significant after adjusting for the ABCG2 421C>A polymorphism. Rosuvastatin Calcium 29-41 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 234-239 23930675-8 2013 CONCLUSION: These findings suggest that the increased plasma concentrations of rosuvastatin in Chinese patients are associated with increased lipid-lowering effects and lower doses of rosuvastatin should be effective in subjects with the ABCG2 421C>A variant. Rosuvastatin Calcium 184-196 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 238-243 23118302-10 2012 In addition, genome-wide significant associations with rosuvastatin-induced change in Lp-PLA(2) activity were observed in ABCG2 and LPA, likely because of their impact on statin-induced low-density lipoprotein cholesterol lowering. Rosuvastatin Calcium 55-67 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 122-127 23289909-7 2013 For example, loss-of-function variants of ABCG2 affect the pharmacokinetics and pharmacodynamics of rosuvastatin in a clinically significant manner. Rosuvastatin Calcium 100-112 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 42-47 23469685-0 2013 ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Rosuvastatin Calcium 116-128 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 47-52 23469685-10 2013 ABCG2 c.421C > A had a significant impact on rosuvastatin pharmacokinetics. Rosuvastatin Calcium 48-60 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-144 21447733-8 2011 Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. Rosuvastatin Calcium 53-65 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 92-96 22081364-9 2012 Genetic polymorphisms observed for BCRP, MDR1, and OATP2B1, and IC(50) determined for hERG blocking lead us to propose that some patients may be at risk of rosuvastatin-induced LQTS. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 35-39 21091277-6 2011 TAKE HOME MESSAGE: The impact of the ABCG2 421C>A polymorphism on the disposition of the statins varies between different drugs and the effect on systemic exposure was greater in the case of rosuvastatin than other statins. Rosuvastatin Calcium 194-206 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 37-42 16784736-0 2006 Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Rosuvastatin Calcium 39-51 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 8-12 20207952-6 2010 An enhanced response to rosuvastatin was seen for patients with variant genotypes of either CYP3A5 (P=0.006) or BCRP (P=0.010). Rosuvastatin Calcium 24-36 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 112-116 20207952-7 2010 Furthermore, multivariate logistic-regression analysis revealed that patients with at least 1 variant CYP3A5 and/or BCRP allele (n=186) were more likely to achieve the LDL cholesterol target (odds ratio: 2.289; 95% CI: 1.157, 4.527; P=0.017; rosuvastatin 54.0% to target vs simvastatin 33.7%). Rosuvastatin Calcium 242-254 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 116-120 20207952-9 2010 CONCLUSION: The LDL cholesterol target was achieved more frequently for the 1 in 3 patients with CYP3A5 and/or BCRP variant genotypes when prescribed rosuvastatin 10 mg, compared with simvastatin 40 mg. Clinical Trial Registration- URL: http://isrctn.org. Rosuvastatin Calcium 150-162 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 111-115 20130569-0 2010 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Rosuvastatin Calcium 90-102 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 20130569-1 2010 The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-27 20130569-1 2010 The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 29-34 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-54 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 215-219 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 234-246 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-54 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 234-246 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 215-219 19474787-0 2009 ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Rosuvastatin Calcium 77-89 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 19474787-7 2009 These results indicate that the ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and, even more so, of rosuvastatin-potentially affecting the efficacy and toxicity of statin therapy. Rosuvastatin Calcium 127-139 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 32-37 18612079-8 2008 Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 70-75 16784736-1 2006 BACKGROUND: Rosuvastatin, a novel potent HMG-CoA reductase inhibitor, is excreted into bile mediated by breast cancer resistance protein (BCRP). Rosuvastatin Calcium 12-24 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 104-136 16784736-1 2006 BACKGROUND: Rosuvastatin, a novel potent HMG-CoA reductase inhibitor, is excreted into bile mediated by breast cancer resistance protein (BCRP). Rosuvastatin Calcium 12-24 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 138-142 16784736-2 2006 Our objective was to determine the association between the most frequent single nucleotide polymorphisms (SNPs) of the BCRP (421C>A) and the pharmacokinetics of rosuvastatin. Rosuvastatin Calcium 164-176 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 119-123 16784736-13 2006 CONCLUSIONS: The BCRP 421C>A polymorphism may play an important role in the pharmacokinetics of rosuvastatin in healthy Chinese males after the exclusion of impact of SLCO1B1 and CYP2C9 genetic polymorphism. Rosuvastatin Calcium 99-111 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 17-21 34668025-0 2022 Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Rosuvastatin Calcium 140-152 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-73 16415124-0 2006 ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Rosuvastatin Calcium 27-39 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 72-104 16415124-3 2006 The present study was designed to determine whether rosuvastatin is transported by MDR1, MRP2, and BCRP. Rosuvastatin Calcium 52-64 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 99-103 16415124-6 2006 In contrast, ATP dramatically stimulated rosuvastatin uptake into membranes expressing BCRP, but not control membranes. Rosuvastatin Calcium 41-53 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 87-91 16415124-9 2006 These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 71-75 16415124-9 2006 These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 93-97 16415124-9 2006 These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin. Rosuvastatin Calcium 145-157 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 93-97 34668025-1 2022 PURPOSE: The study aims to evaluate relationship between polymorphisms associated with a reduced function of two transporter proteins resulting in increased exposure to rosuvastatin - organic anion transporter 1B1 (OATP1B1) (SLCO1B1 c.521T>C) and ATP binding cassette subfamily G member 2 (ABCG2) (ABCG2 c.421C>A) and occurrence of rosuvastatin related myotoxicity/hepatotoxicity. Rosuvastatin Calcium 169-181 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 298-303 34668025-8 2022 CONCLUSION: Loss of function polymorphisms in SLCO1B1 c.521T>C and ABCG2 c.421C>A genes are associated with the presence of rosuvastatin related myotoxicity and/or hepatotoxicity. Rosuvastatin Calcium 124-136 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 67-72 33037044-12 2020 However, consideration of both OATP1B1/3 and gut BCRP inhibition provided a better prediction of the magnitude of the transporter-mediated DDI of these inhibitors with rosuvastatin. Rosuvastatin Calcium 168-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 49-53 35399656-8 2022 The ABCG2 421C>A polymorphism had a significant effect on rosuvastatin exposure but no impact on the interaction with green tea. Rosuvastatin Calcium 58-70 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-9 34603040-9 2021 However, whether the activity of pitavastatin and rosuvastatin is modified by organic anion transporting polypeptide 1B (OATP1B) and of breast cancer resistance protein (BCRP), respectively, in elderly participants with or without CKD was inconclusive. Rosuvastatin Calcium 50-62 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 136-168 34603040-9 2021 However, whether the activity of pitavastatin and rosuvastatin is modified by organic anion transporting polypeptide 1B (OATP1B) and of breast cancer resistance protein (BCRP), respectively, in elderly participants with or without CKD was inconclusive. Rosuvastatin Calcium 50-62 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 170-174 34164937-2 2021 This study employed physiologically-based pharmacokinetic (PBPK) modeling to delineate the effects of inhibitor drugs on BCRP- and organic anion transporting polypeptide (OATP)1B-mediated disposition of rosuvastatin, which is a recommended BCRP clinical probe. Rosuvastatin Calcium 203-215 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 121-125 34164937-2 2021 This study employed physiologically-based pharmacokinetic (PBPK) modeling to delineate the effects of inhibitor drugs on BCRP- and organic anion transporting polypeptide (OATP)1B-mediated disposition of rosuvastatin, which is a recommended BCRP clinical probe. Rosuvastatin Calcium 203-215 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 240-244 34164937-3 2021 Initial static model analysis using in vitro inhibition data suggested BCRP/OATP1B DDI risk for a majority of inhibitors assessed (25 of 27)-which increased rosuvastatin plasma exposure to varying degree (~0-600 %). Rosuvastatin Calcium 157-169 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 71-75 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-67 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 87-91 34162690-5 2021 In our study, apically expressed breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transported atorvastatin, fluvastatin, pitavastatin, and rosuvastatin. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 33-65 34162690-8 2021 The scaled clearances suggest that BCRP contributes to 84-90% and 82% of the total active efflux of rosuvastatin in the small intestine and the liver, respectively. Rosuvastatin Calcium 100-112 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 35-39 34162690-11 2021 These data indicate that BCRP may play an important role in limiting the intestinal absorption and facilitating the biliary excretion of rosuvastatin and that P-gp may restrict the intestinal absorption and mediate the biliary excretion of atorvastatin. Rosuvastatin Calcium 137-149 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 25-29 35152405-5 2022 ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. Rosuvastatin Calcium 92-104 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 35152405-5 2022 ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. Rosuvastatin Calcium 92-104 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 37-41 35335877-0 2022 The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis. Rosuvastatin Calcium 66-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 24-29 35335877-1 2022 Although several studies have revealed the association between rosuvastatin pharmacokinetics and the ABCG2 421C>A (rs2231142) polymorphism, most studies were conducted with small sample sizes, making it challenging to apply the findings clinically. Rosuvastatin Calcium 63-75 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 101-106 35335877-2 2022 Therefore, the purpose of this study is to perform a meta-analysis of the relationship between the ABCG2 421C>A polymorphism and rosuvastatin pharmacokinetics. Rosuvastatin Calcium 129-141 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 99-104 35335877-4 2022 In addition, we reviewed studies published before 12 August 2021, to examine the relationship between the ABCG2 421C>A polymorphism and rosuvastatin pharmacokinetics. Rosuvastatin Calcium 136-148 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 106-111 35335877-12 2022 Therefore, information about ABCG2 genotypes might be useful for individualized rosuvastatin therapy. Rosuvastatin Calcium 80-92 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 29-34 33742787-5 2021 In Trial 1, 5 mg rosuvastatin calcium (BCRP and OATP1B1 substrate) was administered alone, with 90 mg tolvaptan or 48 hours following 7 days of once daily 300 mg tolvaptan (ie, in the presence of DM-4103). Rosuvastatin Calcium 17-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 39-43 32592633-2 2020 The drug-drug interaction potential of aprocitentan on the breast cancer resistance protein (BCRP) transporter substrate rosuvastatin was investigated in this single-center, open-label, single-sequence study. Rosuvastatin Calcium 121-133 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 93-97 32453913-3 2020 Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-22 32453913-3 2020 Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. Rosuvastatin Calcium 82-94 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-22 32453913-3 2020 Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. Rosuvastatin Calcium 82-94 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 60-64 32453913-8 2020 In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing membrane vesicles with a half-maximal inhibitory concentration of 0.35 microM, whereas allopurinol showed no inhibition with concentrations up to 200 microM. Rosuvastatin Calcium 59-71 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-81 32453913-9 2020 Taken together, the results suggest that febuxostat increases rosuvastatin exposure by inhibiting its BCRP-mediated efflux in the small intestine. Rosuvastatin Calcium 62-74 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 102-106 29950617-7 2019 Results revealed that ABCG2 rs2231142 variations were highly associated with the plasma concentrations of RST, RSTL, and DM-RST (Padj < 0.01, FDR < 0.05). Rosuvastatin Calcium 106-109 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-27 32361904-13 2020 CONCLUSION: ABCG2 421C > A (rs2231142) and SLCO1B1 521 T > C (rs4149056) genetic variants affect RST concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers. Rosuvastatin Calcium 97-100 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 12-17 31571146-12 2019 Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 70-74 31102467-6 2019 CsA (blood concentration: 2.77 +- 0.24 muM), an organic-anion-transporting polypeptide, Na+ -taurocholate cotransporting polypeptide, and breast cancer resistance protein inhibitor increased [11 C]RSV systemic blood exposure (45%; P < 0.05), reduced its biliary efflux CL (52%; P < 0.05) and hepatic uptake (25%; P > 0.05) but did not affect its distribution into the kidneys. Rosuvastatin Calcium 197-200 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 138-170 31378968-6 2020 Except for an approximately 80% increase of rosuvastatin AUC (P < .05) in the heterozygotes of ABCG2 c.421C>A relative to the CC genotype, there were no statistically significant associations between rosuvastatin exposure and polymorphisms assessed. Rosuvastatin Calcium 44-56 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 98-103 31857620-0 2019 Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Rosuvastatin Calcium 92-104 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 25-29 31857620-1 2019 A lack of information regarding whether genetic polymorphisms of SLCO1B1 and ABCG2 affect the pharmacokinetics (PKs)/pharmacodynamics (PDs) of rosuvastatin in elderly subjects prevents optimal individualized pharmacotherapy of rosuvastatin in clinical settings. Rosuvastatin Calcium 143-155 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-82 31857620-6 2019 When compared to the subjects with breast cancer resistance protein (BCRP) normal function, the exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function, respectively. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 35-67 31857620-6 2019 When compared to the subjects with breast cancer resistance protein (BCRP) normal function, the exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function, respectively. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 69-73 31857620-6 2019 When compared to the subjects with breast cancer resistance protein (BCRP) normal function, the exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function, respectively. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 174-178 31857620-9 2019 The ABCG2 421C > A polymorphism was associated with the PKs of rosuvastatin and was identified as a more important determinant than the SLCO1B1 521T > C polymorphism in both elderly and young subjects. Rosuvastatin Calcium 63-75 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-9 30921829-5 2019 Furthermore, we found some drug models within the SimCYP library can be improved, e.g., the minor allele frequency of ABCG2 and the fraction metabolized by UGT2B15 should be incorporated for rosuvastatin and lorazepam, respectively. Rosuvastatin Calcium 192-204 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 119-124 30083819-9 2018 Their affinity to the hBCRP ATPase was lower than that of sulfasalazine but comparable to that of rosuvastatin, another hBCRP model substrate. Rosuvastatin Calcium 98-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-27 30083819-9 2018 Their affinity to the hBCRP ATPase was lower than that of sulfasalazine but comparable to that of rosuvastatin, another hBCRP model substrate. Rosuvastatin Calcium 98-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 120-125 29440178-0 2018 Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. Rosuvastatin Calcium 135-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 51-55 29440178-0 2018 Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. Rosuvastatin Calcium 135-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 78-83 29440178-2 2018 The aim of the present study was to estimate quantitatively the influence of c.421C>A on intestinal and hepatic BCRP activity using a physiologically based pharmacokinetic (PBPK) model of rosuvastatin developed from clinical data and several in vitro studies. Rosuvastatin Calcium 191-203 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 115-119 29724614-5 2018 BCRP, MRP3 and MRP4-mediated transport of RSV was observed, and Ko143 inhibited these transporters except MRP3. Rosuvastatin Calcium 42-45 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 28653144-8 2018 RESULTS: Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. Rosuvastatin Calcium 225-237 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 85-90